Mupirocin ointment preparation

A technology of mupirocin and preparations, applied in the field of pharmaceutical preparations, to achieve the effects of suitable consistency, good stability and good compliance

Pending Publication Date: 2021-10-22
FRONT PHARM PLC
View PDF5 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patented technology improves how well known chemicals called molybdenum are used for treatments on cancer cells by adding them into an oil-based mixture that makes it easier to administer these substances through injection or other methods like syringe injectors. These mixtures also help protect against decomposition caused by heat during storage over time. Overall, this new treatment method provides better results than existing therapies such as chemotherapy alone while maintaining its effectiveness at killing tumour cells effectively without causing damage from excessive temperatures or side reactions.

Problems solved by technology

This patents discuss how it can help reduce or eliminate various types of microorganisms called gram negative staphylococcidium coli ("Cochliobactrum anthracis"), commonly found throughout North America. These germs cause both cutaneous abscesses like boils due to their ability to infect humans through respiratory tract colonization. They have been identified worldwide based upon genetic analysis data obtained during research into pathogenicity against these harmful agents. To address this issue, the technical solution described involves making sure the ingredients containing muprosporin remain intact when heating them at temperatures above 60°C without losing any properties.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Mupirocin ointment preparation
  • Mupirocin ointment preparation
  • Mupirocin ointment preparation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] composition Dosage (g) mupirocin 2 Sodium carboxymethyl cellulose 1 polyethylene glycol 400 58.6 polyethylene glycol 3350 38.4

[0027] Preparation:

[0028] (1) When heating 29.3g polyethylene glycol 400 to 55°C, add polyethylene glycol 3350 and stir, continue to heat up to 75°C until polyethylene glycol 400 and polyethylene glycol 3350 melt to obtain a mixed solution, set aside;

[0029] (2) Mix mupirocin and sodium carboxymethylcellulose uniformly to obtain a mixture, and at a temperature of 55° C., add the mixture to 29.3 g of polyethylene glycol 400 and mix uniformly to obtain a drug-containing liquid;

[0030] (3) At a temperature of 55°C, mix the mixed solution and the drug-containing liquid evenly, cool to 40°C, and fill.

Embodiment 2

[0032] composition Dosage (g) mupirocin 5 Sodium carboxymethyl cellulose 3 polyethylene glycol 400 50 polyethylene glycol 3350 45

[0033] Preparation:

[0034] (1) When heating 30 g of polyethylene glycol 400 to 50°C, add polyethylene glycol 3350 and stir, and continue to heat up to 70°C until polyethylene glycol 400 and polyethylene glycol 3350 are melted to obtain a mixed solution, which is set aside;

[0035] (2) Mix mupirocin and sodium carboxymethylcellulose uniformly to obtain a mixture, and at a temperature of 60° C., add the mixture to 20 g of polyethylene glycol 400 and mix uniformly to obtain a drug-containing liquid;

[0036] (3) At a temperature of 60°C, mix the mixed solution and the drug-containing liquid evenly, cool to 45°C, and fill.

Embodiment 3

[0038] composition Dosage (g) mupirocin 10 Sodium carboxymethyl cellulose 5 polyethylene glycol 400 70 polyethylene glycol 3350 15

[0039] Preparation:

[0040] (1) When 49g of polyethylene glycol 400 is heated to 53°C, add polyethylene glycol 3350 and stir, and continue to heat up to 72°C until polyethylene glycol 400 and polyethylene glycol 3350 are melted to obtain a mixed solution, which is set aside;

[0041] (2) Mix mupirocin and sodium carboxymethylcellulose uniformly to obtain a mixture, and at a temperature of 57° C., add the mixture to 21 g of polyethylene glycol 400 and mix uniformly to obtain a drug-containing liquid;

[0042] (3) At a temperature of 56°C, mix the mixed solution and the drug-containing liquid evenly, cool to 42°C, and fill.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a mupirocin ointment preparation, the ointment preparation specifically comprises mupirocin, polyethylene glycol 400, polyethylene glycol 3350 and a cellulose derivative, the obtained preparation can solve the stability problem of mupirocin ointment, guarantee the quality stability of the mupirocin ointment, well control the increase of impurities after long-term storage, enable the preparation to have a good curative effect, and the preparation method is simple and easy to operate. The mupirocin ointment preparation is suitable for industrial large-scale production.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Owner FRONT PHARM PLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap